Table 1. Baseline demographics.
| Baseline Demographics | ||||
|---|---|---|---|---|
| Variable | All patients (n = 236) | NCT (n = 98) | NCAT (n = 138) | p-value |
| Age | 50.4 (10.9) | 51.4 (11.0) | 49.7 (10.8) | 0.2506 |
| Histological type | ||||
| IDC | 223 (94.5) | 93 (94.9) | 130 (94.2) | |
| Other | 13 (5.5) | 5 (5.1) | 8 (5.8) | 0.529 |
| Tumour size | ||||
| <20 mm | 16 (6.8) | 3 (3.1) | 13 (9.4) | |
| 20–50 mm | 146 (61.9) | 62 (63.3) | 84 (60.9) | |
| >50 mm | 57 (24.2) | 25 (25.5) | 32 (23.2) | |
| Inflammatory/Others | 17 (7.2) | 8 (8.2) | 9 (6.5) | 0.278 |
| Tumour grade | ||||
| 1–2 | 75 (31.8) | 21 (21.4) | 54 (39.1) | |
| 3 | 135 (59.2) | 58 (57.2) | 77 (55.8) | |
| Not Available | 26 (11.0) | 19 (19.4) | 7 (5.1) | <0.001 |
| Estrogen receptor status | ||||
| Positive | 124 (52.5) | 50 (51.0) | 74 (53.6) | |
| Negative | 111 (47.0) | 48 (49.0) | 63 (45.7) | |
| Not Available | 1 (0.4) | 0 | 1 (0.7) | 0.632 |
| Chemotherapy regimen | ||||
| Anthracycline | 98 (41.5) | 26 (26.5) | 72 (52.2) | |
| AnthracyclineTaxane | 118 (50.0) | 58 (59.2) | 60 (43.5) | |
| Taxane | 5 (2.1) | 3 (3.1) | 2 (1.5) | |
| Other | 15 (6.4) | 11 (11.2) | 4 (2.9) | <0.001 |